阿霉素联合重组人血管内皮抑制素对人骨肉瘤细胞OS-732作用的体外实验研究

In vitro study of recombinant human endostatin in combination with adriamycin on human osteosarcoma cell OS-732

目的确定阿霉素和重组人血管内皮抑制素两种药物联合对人骨肉瘤细胞的体外作用。方法阿霉素、重组人血管内皮抑制素及两药联用处理人骨肉瘤细胞OS-732,分别在24h、72h及144h应用MTT法测定其细胞毒性,同时用倒置相差显微镜观察细胞形态学改变。结果在阿霉素10μg/ml和100μg/ml作用72h和144h后,细胞增殖活性受抑制率达到50%以上,重组人血管内皮抑制素在第72h时对骨肉瘤细胞抑制率为7.3%～9.2%,联合用药组细胞增殖活性与阿霉素单药组无显著性差异。阿霉素和联合用药组细胞均发生细胞变小,核碎裂,失去细胞正常形态,而重组人血管内皮抑制素单药组细胞形态与对照组相似。结论重组人血管内皮抑制素仅在给药后短期内对人骨肉瘤细胞有轻度的抑制作用,重组人血管内皮抑制素不影响阿霉素对骨肉瘤细胞的细胞毒作用。

Objective To evaluate the effect of adriamycin combined with recombinant human endostatin on human osteosarcoma cell OS-732. Methods Adriamycin, recombinant human endostatin and the combination of these two drugs were used to treat OS-732 human osteosarcoma cell respectively. Cell count and MTT assay were used to record the cytotoxicity 24h, 72h and 144 h after medication. Cellular morphologic changes were observed thorugh phase contrast microscope. Results The inhibition rate of cell proliferation and cellular activity was more than 50%, 72h and 144h after adriamycin infusion（10μg/ml and 100μg/ml）. The inhibition rate of osteosarcoma cell activity was 7.3% - 9.2% 72h after the recombinant human vessel endostatin infusion. No significant differenceof cell proliferation was found between the combination treatment group and the adriamycin group. Conclusion Recombinat human vessel endostation has minor inhibiting effect on human osteosarcoma shortly after the treatment. It does not compromise the inhibitive effect of adramycin on human osteosarcoma cells.